Cigna says it is not pursuing deal with rival Humana, shares rise
Adds share movement in paragraph 3; analyst comment in paragraphs 4; graphic
By Sriparna Roy and Mariam Sunny
Nov 11 (Reuters) -Cigna Group CI.N said on Monday it is not pursuing a combination with rival health insurer Humana HUM.N, days after Donald Trump's reelection as U.S. president raised investor hopes that any merger would face far less antitrust scrutiny.
Humana shares rose after Tuesday's election as investors bet on an easier antitrust review for any mega-merger during a Trump administration, analysts said.
On Monday, Humana shares fell 4% to $276.44 in early trading, while Cigna was up more than 7% at $343.53.
"Cigna's latest clarification certainly puts the possibility of such a deal to bed," Oppenheimer analyst Michael Wiederhorn said in a research note. Humana's stock will remain under pressure following the news, he added.
The company in its release said it remains focused on acquisitions that are "strategically aligned, financially attractive and have a high probability to close."
Humana did not immediately respond to a Reuters request for comment.
Bloomberg News reported in October that Cigna had revived efforts to merge with Humana. That came after Reuters reported last year that Cigna had ended its attempt to negotiate an acquisition after the pair failed to agree on a price.
Cigna also said it expects to actively repurchase shares in the fourth quarter and in 2025. The company said it was making the announcement ahead of meetings with investors and analysts over the next several weeks.
Morningstar analyst Julie Utterback called Cigna's announcement unusual and said the move was aimed at removing pressure on its stock.
"With the Republican win last week, there was speculation by investors that the antitrust concerns may decline enough to make the deal possible," Utterback said.
Cigna, which manages employer-sponsored healthcare plans and runs a pharmacy benefit manager, is in the process of selling its Medicare Advantage business, which manages government-backed health insurance for people aged 65 and older.
Last month, Cigna CEO David Cordani described the Medicare Advantage market as highly disrupted and said the company was focused on share buybacks.
Humana shares rise as Trump victory boosted hopes of the reported deal https://tmsnrt.rs/3Ar9ks9
Reporting by Mariam Sunny and Sriparna Roy in Bengaluru; additional reporting by Amina Niasse; Editing by Shilpi Majumdar and Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
